324387
Dopamine Receptor Antagonist II, Thioridazine, HCl
The Dopamine Receptor Antagonist II, Thioridazine, HCl, also referenced under CAS 130-61-0, controls the biological activity of Dopamine Receptor. This small molecule/inhibitor is primarily used for Biochemicals applications.
别名:
Dopamine Receptor Antagonist II, Thioridazine, HCl, 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylthio)-10H-phenothiazine, HCl, 10-(2-(1-methylpiperidin-2-yl)ethyl)-2-(methylthio)-10H-phenothiazine, HCl
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C21H26N2S2 · xHCl
化学文摘社编号:
分子量:
370.57 (free base basis)
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
Storage condition:
OK to freeze, desiccated (hygroscopic), protect from light
Quality Level
assay
≥98% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated (hygroscopic), protect from light
color
off-white
solubility
water: 25 mg/mL
shipped in
ambient
storage temp.
2-8°C
InChI
1S/C21H26N2S2.ClH/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23;/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3;1H
InChI key
NZFNXWQNBYZDAQ-UHFFFAOYSA-N
General description
A phenothiazine class antipsychotic and dopamine receptor (DR) antagonist that is reported to exhibit CSCs- (cancer stem cells) differentiating (EC50 ≤9.4 µM for v1H9) and anti-leukemic activity, without affecting non-neoplastic H9 hESC, adult fibroblast-derived iPSC, or HSPCs (hematopoietic stem-progenitor cells). However, Thioridazine′s high effective concentration (10 µM) against cancer cells suggests that other unidentified cellular targets/mechanisms in addition to DR antagonism may be also involved in its overall anti-CSC impact. Effectively augments AraC (Cat. No. 251010 ) in inhibiting primary AML in vitro colony formation (by 79%, 55%, and 100%, respectively, with 10 µM Thioridazine, 0.1 µM AraC, or a combination of both).
A phenothiazine class dopamine receptor (DR) antagonist that, in addition to its well known clinical use as an antipsychotic for schizophrenia treatment, is also reported to selectively induce the differentiation of neoplastic v1H9 (EC50 ≤9.4 µM in Oct4-GFP reporter assay) and v2H9, but not their parent non-neoplastic H9 hESC or adult fibroblast-derived iPSC. Both Thioridazine′s CSCs- (cancer stem cells) selective differentiation effect and anti-leukemic activity correlate well with the selective DR expression on CSCs and AML cells, but not H9, iPSC, normal HSCs (hematopoietic stem cells) or HSPCs (hematopoietic stem-progenitor cells). However, Thioridazine′s high effective concentration (10 µM) against cancer cells suggests that other unidentified cellular targets/mechanisms in addition to DR antagonism are involved in its overall anti-CSC impact. Effectively augments AraC (Cat. No. 251010 ) in inhibiting primary AML in vitro colony formation (by 79%, 55%, and 100%, respectively, with 10 µM Thioridazine, 0.1 µM AraC, or a combination of both) without exerting cytotoxic effect on normal HSPCs.
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Sachlos, E., et al. 2012. Cell149, 1284.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Regulatory Review (Z)
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
法规信息
新产品
此项目有
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 324387-2GM | 04055977216509 |